Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback